A Phase 1, Multicenter, Open-Label, Dose Escalation Trial of PDL192 in Subjects With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 05 Jan 2012
At a glance
- Drugs Enavatuzumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 05 Jan 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 05 Jan 2012 Actual patient number is 30 according to ClinicalTrials.gov.
- 05 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.